Patents

U.S. government grants patent for MVA-BN vaccine

Published in TB and Outbreaks Week, August 17th, 2004

Bavarian Nordic A/S announced that the United States Patent and Trademark Office (USPTO) has issued a patent to the company on its proprietary MVA-BN technology.

The patent grants exclusive rights to Bavarian Nordic upon issuance (of U.S. Patent 6,761,893) and claims MVA-BN and derivatives thereof.

Safety in humans continues to be the overriding challenge in vaccine development and production. The USPTO's patent grant to the MVA-BN virus, which is nonreplicative in humans, acknowledges the novelty and utility of such a virus exhibiting the demonstrated excellent safety profile of the MVA-BN technology and other claimed MVA viruses exhibiting similar...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-08-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry